FOLFIRI Protocol clinical trials

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

This study looks at new drug combinations (Durvalumab and Tremelimumab with FOLFIRI chemotherapy) for advanced stomach or food pipe cancer that has already been treated. It aims to see how well patients respond and if these combinations can help people live longer.